Powerful Molecular Test to Assess Patient Risk of Prostate Cancer
PCA3Plus®, offered by Bostwick Laboratories, is a urine assay used
with men that have a negative or atypical prostate biopsy combined with high or rising PSA.
It helps determine which patients should undergo active monitoring and possibly a second
biopsy.* By measuring the ratio of PCA3 mRNA to PSA mRNA, PCA3Plus helps to identify patients
who are at a greater risk for prostate cancer on a follow-up biopsy.
- The first urine-based genetic test for prostate cancer risk
- Ideal for men over 50 with rising PSA and negative biopsy
- Urine-based, non-invasive molecular test
- Quantitative test with measurable results
- The Progensa® PCA3 assay is FDA approved
PCA3 is superior to percentage of free PSA as a predictor of the repeat biopsy outcome. A higher
PCA3 score may also correlate to the significance of prostate cancer.1 Additionally, a higher
PCA3 score is associated with higher tumor volume and Gleason score.2
- PCA3Plus is a genetic test looking at the PCA3 gene over-expressed in prostate cancer cells.
- PCA3Plus is a much more specific method to identify patients at risk for prostate cancer.
- PCA3Plus has a higher specificity than serum PSA with a <1% non-informative rate.
*Not recommended for men with atypical small acinar proliferation (ASAP) on their most recent
biopsy. These patients should be treated based upon current medical guidelines.
1. Haese A, et al., Clinical Utility of the PCA3 Urine Assay in European Men Scheduled for
Repeat Biopsy, Eur Urol (2008), doi:10.1016/j.eururo.2008.06.071
2. Nakanishi H, Groskopf J, Fritsche, HA, et al. PCA3 Molecular Urine Assay Correlates with
Prostate Cancer Tumor volume: Implication in Selecting Candidates for Active Surveillance. J Urol 2008; 179:1804-9
3. Marks L S, et al., Prostate Cancer Specificity of PCA3 Gene Testing: Examples from Clinical Practice, Rev Uro 2008; 10(3): 175-181
4. Groskopf, Jack, PhD, senior research scientist, Gen-Probe Inc., Reprint from Urology Times, July 2006